title: [Acute diffuse interstitial pneumopathy following docetaxel (Taxotère). Apropos of 2 cases].
abstract: Docetaxel, a new chemotherapeutic agent, has demonstrated activity in non-small cell lung cancer and breast cancer. Toxicities associated with treatment using docetaxel include hypersensitivity reactions and fluid retention, which can be prevented by pretreatment with corticosteroids. We describe herein two cases of acute interstitial pneumonitis after administration of docetaxel to patients suffering from metastatic non-small cell lung cancer. A pulmonary toxicity of docetaxel from an hypersensitivity reaction is likely because of symptoms course, radiological demonstration of an interstitial pneumonitis, lack of an infectious etiology and of clinical response to antibiotic treatment, and rapid recovery with corticosteroids. This unusual pulmonary toxicity has been rarely described with docetaxel, as transient pulmonary infiltrates have been observed during treatment with paclitaxel. The possibility of an hypersensitivity pneumonitis must be taken into account when a patient with docetaxel treatment presents pulmonary infiltrates.
authors.affiliation: Service de Pneumologie, Hôpital de la Croix-Rousse, Lyon.
authors.forename: B
authors.initials: B
authors.lastname: Etienne
authors.forename: M
authors.initials: M
authors.lastname: Pérol
authors.forename: P
authors.initials: P
authors.lastname: Nesme
authors.forename: S
authors.initials: S
authors.lastname: Vuillermoz
authors.forename: G
authors.initials: G
authors.lastname: Robinet
authors.forename: J C
authors.initials: JC
authors.lastname: Guérin
mesh_terms: D000368:Aged; D000542:Alveolitis, Extrinsic Allergic / Q000139:chemically induced / Q000188:drug therapy; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000556:secondary; D000077143:Docetaxel; D004342:Drug Hypersensitivity / Q000188:drug therapy / Q000209:etiology; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008168:Lung / Q000187:drug effects; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D017239:Paclitaxel / Q000009:adverse effects / Q000031:analogs & derivatives*; D011239:Prednisolone / Q000627:therapeutic use; D011654:Pulmonary Edema / Q000139:chemically induced / Q000188:drug therapy; D043823:Taxoids
chemical_list: D000893:Anti-Inflammatory Agents; D000972:Antineoplastic Agents, Phytogenic; D005938:Glucocorticoids; D043823:Taxoids; D000077143:Docetaxel; D011239:Prednisolone; D017239:Paclitaxel
vernacular_title: Pneumopathie interstitielle diffuse aiguë sous docétaxel (Taxotère). A propos de 2 observations.